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fluid to be sure of such an outcome.3 These are issues
that must be dealt with in future reports—as must the
accountability of other players, such as foundations
and non-governmental organisations.
The global health governance system needs a
strong core that develops and monitors norms and
standards including international health treaties,
tackles key health issues of the poor, and ensures
global health security through international regula-
tions, surveillance, and rapid outbreak response. With
this in mind, the chapter analysing WHO and the lead-
ership and governance problems it faces is one of the
most worrying in this report. The report makes specific
proposals for a stronger WHO, for better funding and
organisation of global health, and for cooperation
between civil society movements committed to global
public goods such as water, education, and health. It
also proposes a global campaign for a tax to finance
global public goods. How difficult such a shift will be
could be seen at the recent G8 summit.4 Even so, when
public health experts suggested a tax on airline tickets
for global public health several years ago,5 6 they were
considered dreamers; now this issue is part of the
deliberation of heads of state, and airlines would do
well in spearheading a movement for global health
security on which their business depends.
I would hesitate to put most of the reason for
failure down to the all encompassing concepts of neo-
liberalism and globalisation, as the alternative world
health report is prone to doing, but health is deeply
political. We need to tackle the political determinants
of health. National public health associations and
medical associations should be at the forefront of
explaining and exploring the interface of national and
global public health, maybe through the mechanism of
national global health summits.7 They should commit
to this unique historical opportunity, which is like the
19th century golden age of public health. Then as now:
if we want “to make poverty history,” we need to tackle
health.
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Evidence based prescribing
Is the goal, but prescribers still need education, experience, and common sense
Evidence based medicine has been defined as “theconscientious, explicit, and judicious use ofcurrent best evidence in making decisions about
the care of individual patients.”1 Few areas of medical
practice have felt the effects of this movement more
clearly than prescribing. Until recently doctors could
prescribe medicines without worrying that their choices
might be judged against evidence accumulated in the
world’s literature. Now, prescribers are increasingly
expected to back up their decisions with evidence.2
Enthusiasm for evidence based prescribing is welcome
and should lead to safer and more effective use of
medicines. But it also poses some real problems for
prescribers.
Reliable information to underpin everyday pre-
scribing decisions at the point of prescription is hard to
find. One solution is to provide modern information
technology systems in the consulting roomor at the bed-
side.3 But even these may deliver too much unfiltered
information including some original research, some
guidance derived from research, and some unsubstanti-
ated opinion. The modern prescriber has to decide
which data are the most reliable, accurate, and
representative of true evidence rather than conjecture.
What should the prescriber do, however, if he or
she finds several apparently reliable sources giving dif-
fering advice about the same clinical problem? In this
issue of the BMJ Vidal et al (p 263) compare the advice
given in four respected prescribers’ guides on adjusting
in renal impairment the dosages of 100 commonly
used drugs.4 They find that the four texts differ in their
recommendations on dose and dosing interval, and
even in their definition of renal impairment. They con-
clude that this variation is “remarkable,” as is the lack of
detail about how the advice was reached, and describe
the sources as “ill suited for clinical use.” These conclu-
sions seem harsh and deserve further analysis.
Should we be surprised that respected texts vary?
Probably not. Even when there is very good evidence—
for example for managing hypertension—different
experts may synthesise it to produce a variety of
conclusions about optimal prescribing.5 6 Vidal et al
focus on recommended adjustments in dose for a rela-
tively small proportion of patients with a problem that
is much rarer than hypertension. In more than half the
instances of discrepant advice, the authors acknowl-
edge that they could find no firm evidence despite
prolonged searching of Medline.4 Clinicians often have
no relevant scientific evidence on which to base a deci-
sion.7 Rapid accumulation of research findings and
international efforts to sort and rationalise them
systematically are closing some of these gaps in
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evidence, but new gaps will continue to appear. In the
absence of unambiguous evidence covering all eventu-
alities differences of opinion are inevitable, even
among the most reliable sources of guidance.
Furthermore, should respected sources such as the
British National Formulary (BNF) be expected to
provide details about how they reach their advice?
Three of the four texts compared in this study provide
information relevant to much of the population on the
use of several thousand medicines. Vidal et al focused
on the prescribing of 100 drugs in circumstances that
affect only a small proportion of people. Their call for
clarification of the evidence behind the advice that
interests them ignores the difficulties of providing
similar backing for hundreds of thousands of other
similar items of prescribing information. The task
would be beyond most editorial groups.
Many items of prescribing information probably
cannot yet be matched to primary evidence. Even
when such evidence can be found, it is often inconclu-
sive, inconsistent with other studies, irrelevant to clini-
cal realities, or of poor quality. Systematic reviews solve
some of these problems, but they too may reach vary-
ing recommendations because of differing designs.8
Most users of the BNF probably prefer a text that sum-
marises best practice and does not describe the totality
and complexity of evidence that goes into creating it.
The BNF is probably better “suited for clinical use”
because of its relative simplicity.
These caveats should not lessen our appetite for
sound, evidence based recommendations for rational
prescribing. Vidal et al are right to remind us that,
where possible, such recommendations should be
referenced and open to scrutiny. However, these ideals
have to be seen in context. Most prescribers are prob-
ably willing to accept the advice provided by a trusted
source in the knowledge that, if they want to see the
existing evidence, they have relatively easy access to it
through searches of Medline and other databases and
resources such as Clinical Evidence.
Prescribing will always be too complex for all
the answers to be evidence based and “grey zones”7
will always be there. Even when the best course of
action seems clear, evidence has to be interpreted in
the light of variables such as patients’ comorbidities
and drug interactions. To cope with these uncertainties,
prescribers will still need a combination of clinical
experience, common sense, and knowledge based
on a firm grounding in the principles of clinical
pharmacology.9 10
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Making prison health care more efficient
Inmates need more organised and more preventive health care in emptier prisons
The cost of providing prison health services hasbeen debated since 1774, when the Health ofPrisoners Act was passed by the British parlia-
ment.1 That debate continues now, although measur-
ing how much taxpayers spend on prisoners is
notoriously difficult. Nevertheless, the annual median
cost of incarcerating a prisoner in secure custody in
2003-4 was about $28 000 (£15 800, €23 400) per
state prisoner in the United States,2 $45 000 in
Australia,3 and $53 000 in Britain.4 w1 US state prison-
ers’ annual healthcare costs averaged 12% of total
costs (around $3350). With rising rates of incarcera-
tion,w2 increasing public support for penal policies,w3
greater needs among inmates for health care,5 and
limited budgets,w4 prison health care is becoming
harder to fund adequately.
In September 2002, the British government
announced that it would transfer budgetary responsi-
bility for prison health from the Prison Service to the
Department of Health. By April 2006 responsibility for
commissioning prison health care will be devolved to
NHS primary care trusts.w5 Elsewhere, many custodial
authorities have implemented strategies such as
managed care and copayment schemes to reduce pres-
sure on prison health budgets. In the first three years of
the introduction of managed care to Texan prisons, for
example, the daily healthcare costs for each prisoner
fell from $5.98 to $5.11.w6
Since prisoners are not generally paying custom-
ers, healthcare providers have little incentive to
provide good quality care: indeed, they have a
perverse incentive to minimise essential services that
have high costs. Doctors and nurses generally have to
seek approval from managed care organisations to
request tests and surgical procedures, but such
approval is sometimes so slow in prisons that it arrives
after an inmate is released or transferred.w7 In the US,
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